VEGFA and breast carcinoma: Also BEZ-235 potently inhibits VEGF-induced cell proliferation and survival in vitro and VEGF-induced angiogenesis in vivo [142], and effectively reverses lapatinib-resistance in HER2 breast cancer cells [143].